Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus DORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus DORAL.
CHLORDIAZEPOXIDE HYDROCHLORIDE vs DORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and reduced excitability.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Oral: 5-25 mg 3-4 times daily, up to 100 mg/day in severe anxiety; IM/IV: 50-100 mg initially, then 25-50 mg 3-4 times daily.
15-30 mg orally at bedtime, maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6.6 to 28 hours (parent drug); clinically, duration of effect may be prolonged due to active metabolite nordazepam (half-life 30-100 hours), especially in elderly or hepatic impairment.
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Renal: approximately 50-60% as metabolites (mainly conjugated forms), with less than 1% unchanged. Fecal: minor, about 10%. Biliary excretion contributes to enterohepatic circulation.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Category D/X
Category C
Benzodiazepine
Benzodiazepine